The authors thank Robert Choy and Geno De Hostos from PATH (San Francisco, CA) for their consultation on the drug development process, Melissa S. Love from Calibr (Scripps Research Institute, La Jolla, CA) for conducting the Calbr Cryptosporidium panel screen, and Gail M. Freiberg, Bruce LeRoy, and Dale J. Kempf (AbbVie, Chicago, IL) for coordinating in vitro and in vivo testing services. University of Washington has utilized the non-clinical and preclinical services program offered by the National Institute of Allergy and Infectious Diseases for rat and dog toxicology testing.